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Acne inversa (AI; also designated as hidradenitis suppurativa) is a chronic inflammatory disease with still unknown pathogenesis
that affects the intertriginous skin of perianal, inguinal, and axillary sites. It leads to painful nodules, abscesses, and fistulas
with malodorous secretion and is frequently associated with metabolic alterations. Here, we demonstrate that one of the most
highly upregulated molecules in AI lesions is matrix metalloproteinase 8 (MMP8), an enzyme specialized in the degradation of
extracellular matrix components and the HDL component apolipoprotein A-I. Granulocytes, which were present in AI lesions,
secreted high amounts of MMP8 especially after TNF-𝛼 stimulation. Furthermore, activated fibroblasts but not keratinocytes were
found to express MMP8.The high lesional MMP8 levels were accompanied by elevated blood levels that positively correlated with
TNF-𝛼 blood levels and disease severity assessed by Sartorius score, especially with the number of regions with inflammatory
nodules/abscesses and fistulas. Additionally, we found a negative correlation between blood MMP8 and HDL-cholesterol levels,
suggesting a contributory role of MMP8 in metabolic alterations in AI. In summary, we demonstrate elevated MMP8 levels in AI
lesions, suggest their role in skin destruction and metabolic alterations, and recommend the use of MMP8 as blood biomarker for
AI disease activity assessment.
1. Introduction
Acne inversa (AI, also referred to as hidradenitis suppurativa)
is a chronic inflammatory skin disease with common onset
in the second or third decade of life [1, 2]. Estimates of the
prevalence of AI have varied, ranging from less than 1 percent
to 4 percent [3, 4]. AI primarily occurs on intertriginous skin.
The axilla and the inguinal, gluteal, and perianal area are
the most common affected sites. The inner thighs, perineal
areas, sub- and inframammary skin, and gluteal cleft are
additional sites for involvement [1, 2]. The clinical manifes-
tation progresses from nodules and inflamed lesions with
deep abscesses to chronic, draining sinus tracts and bands
of severe scar formation. The associated pain, large amount
of purulent exudate, malodor, and disfigurement contribute
to a profound psychosocial impact of the disease on affected
patients [3, 5, 6]. Additionally, AI is frequently associated
with metabolic alterations that might increase the risk of
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cardiovascular disorders and reduce the life expectancy [7, 8].
An early and accurate diagnosiswould allow the initiation of a
treatment plan aimed atminimizing the risk of progression to
disabling, end-stage disease. However, as of today, on average
12 years pass between first symptoms and accurate diagnosis
[9].
The pathogenesis of AI is still widely unknown. The
current model implies that the follicular occlusion of the
pilosebaceous unit by infundibular hyperkeratosis leads to
dilatation and rupture of the unit as initial steps [1]. At
very early stages of the disease, there is already a slight
perifollicular infiltration of immune cells [10]. Chronic AI
lesions feature immune cell infiltration and strong expression
of numerous proinflammatory cytokines like TNF-𝛼 and IL-
17A [11]. The inflammation seems to increase the destruction
of skin architecture and the development of deep fistulating
sinuses [12].
Currently, the disease severity of AI can be assessed
by using two clinical scores. The Hurley classification is a
simple system that divides AI into three severity grades for
each area involved [13]. Originally, the score was designed
to help decide if surgery is indicated. However, it is static
and not suitable for the assessment of inflammatory aspects
of the disease. Secondly, the Sartorius score [14] with its
modified versions [15, 16] is a dynamic score that takes
into account numerous parameters including the number
of affected regions, the type of cutaneous alteration, lesion
diameters, and the presence of healthy skin between lesions.
The Sartorius score yields a count between zero (inactive
disease) and about 250. It requires some experience and its
alterations may result from changes in various aspects of
the disease. Furthermore, to a certain extent both scores
lack objectivity, with the final evaluation being dependent
on the examiner’s interpretation of the physical findings. In
our study we aimed to investigate the possible suitability
of MMP8 as blood biomarker that could be exactly and
easily quantified and help to assess disease activity in AI.
Furthermore, we wanted to explore the cellular source of
MMP8 as well as its role in AI pathogenesis.
2. Materials and Methods
2.1. Patients. Skin biopsies for gene expression analyses by
means of polymerase chain reaction on reversely transcribed
RNA (RT-qPCR) were obtained from 8 control participants,
10 patients with AI, and 10 patients with psoriasis. The skin
biopsies of AI patients were taken from surgically excised
skin areas and such biopsies were also used for immunohis-
tochemistry (IHC). Blood plasma and serum were obtained
from 20 control participants [27 to 57 years old (mean ±
SD: 39.0 ± 9.3 years), 25% male] and from 21 patients with
AI [22 to 56 years old (mean ± SD: 41.7 ± 11.6 years),
10% male, Sartorius score: 52.9 ± 40.9 (mean ± SD)]. There
were no significant differences in age or sex distribution
between control participants and AI patients. All skin and
blood samples were approved by the clinical institutional
review board of the Charite´ university hospital, Berlin, and
written consent was obtained from all participants.The study
was conducted according to the principles expressed in the
Declaration of Helsinki.
2.2. Cell Culture. Human blood was diluted 1 to 5 with
RPMImedium and stimulated or not (control) with 10 ng/mL
IFN-𝛾, 5 ng/mL TNF-𝛼, 5 ng/mL IL-1𝛽, 10 ng/mL IL-6,
10 ng/mL IL-17A, or 20 ng/mL IL-22 for 4 h to activate neu-
trophilic granulocytes. Primary dermal fibroblasts (Lonza/
Life Technologies/Promocell) and primary human keratino-
cytes (Lonza) were cultured in FGM-2 medium and KGM-
Gold medium, respectively (both from Lonza), according to
the suppliers instructions and as previously described [17, 18].
Fibroblasts were stimulated or not (control) with 10 ng/mL
IFN-𝛾, 5 ng/mL TNF-𝛼, 10 ng/mL IL-17A, 50 ng/mL IL-19, or
20 ng/mL IL-24 for 24 h. Keratinocyteswere stimulated or not
(control) with 10 ng/mL TNF-𝛼, 10 ng/mL IL-17A, 10 ng/mL
IL-22, or indicated combinations thereof for 6 h.All cytokines
mentioned above were purchased from R&D Systems.
2.3. RT-qPCR. Tissue homogenization, isolation of total cel-
lular RNA, mRNA reverse transcription, and qPCR analysis
were done as previously described [19, 20]. Detection sys-
tems using fluorescent probes were purchased from Applied
Biosystems. Expression valueswere normalized to abundance
of mRNA transcripts of the house-keeping gene human
hypoxanthine-guanine phosphoribosyltransferase 1 (HPRT).
2.4. ELISA. Detection of human MMP8 (lithium heparin
plasma), TIMP-4 (lithium heparin plasma), TNF-𝛼 (serum),
and resistin (EDTAplasma)was performed usingQuantikine
systems from R&D Systems. Quantification of plasma lipids
was carried out using Cobas 8000 modular analyzer series,
Roche Diagnostics GmbH.
2.5. IHC. Skin biopsies were fixed in 10% neutral buffered
formalin, embedded in paraffin, routinely processed, sec-
tioned at 5 𝜇m, and stained with antibodies (Ab) recognizing
myeloperoxidase (Dako). Detection of primary Ab binding
was performed using biotinylated polyclonal rabbit anti-rat
IgG, streptavidin horseradish peroxidase andAEC+ substrate
(all from DAKO), or the LSAB2 System-HRP kit (DAKO);
counterstaining was done with hematoxylin.
2.6. Statistical Analysis. Data are presented as the mean
± SEM. For further analyses, SPSS 19.0 software (IBM)
was used. Results from patients/control participants were
analyzed using the Mann-Whitney U test (two-tailed). Cor-
relations were analyzed based on Spearman’s rank correlation
test. Results on primary cell cultures were tested using the
Wilcoxon matched-pairs signed-rank test (two-tailed).
3. Results
3.1. MMP8 Is Strongly Expressed in Lesional AI Skin. The
mechanisms associated with the development and progres-
sion of AI lesions (Figure 1(a)) are still enigmatic. To identify
potential key players in these processes, we first individually
quantified the expression of a broad range of immune
























Figure 1: MMP8 expression is elevated in lesional skin of AI patients. (a) Picture of affected gluteal skin of a 53-year-old patient suffering
from AI with inflammatory lesions and fistulas. (b) MMP8 expression was analyzed in biopsies from skin of 8 healthy control donors and the
lesional skin of 10 AI and 10 psoriasis patients by RT-qPCR. Mean data ± SEM are shown. Significance of differences was analyzed using the
Mann-Whitney U test (two-tailed; ∗∗𝑃 < 0.01).
parameters in affected skin of AI patients and skin from
control participants. From 25 investigated mediators [IL-4,
IL-6, IL-13, IL-20, IL-25, IL-33, IL-34, IL-12 p35, IL-23 p19,
p40, IFN-𝛾, GM-CSF, CCL2, CCL8, CCL17, CCL20, CCL22,
CCL26, CXCL2, CXCL9, CXCL10, CXCL11, 𝛽-defensin (BD)-
1, BD3, metalloproteinase (MMP) 8, and CD54], MMP8 was
the parameter with the highest upregulation in AI lesion
compared to skin from control participants. MMP8 (also
referred to as collagenase 2) is an enzyme specialized in
the degradation of extracellular matrix components [21].
The elevated expression of MMP8 in lesional AI skin may
therefore be involved in the development of draining sinus
tracts and the destructive character of this disease. Inter-
estingly, increased MMP8 expression was specific for AI
lesions and not observed in affected skin of patients with
psoriasis, a chronic inflammatory skin disease without sinus
tract development (Figure 1(b)).
3.2. TNF-𝛼 Is a Strong MMP8 Inducer. Next, we focussed
on MMP8 production. MMP8 is known to be stored in
secondary granules within neutrophilic granulocytes and
secreted in its active form [21]. Because marked pres-
ence of neutrophilic granulocytes was found in AI lesions
(Figure 2(a)), we firstly investigated different AI-relevant
cytokines for their ability to induce MMP8 secretion from
neutrophilic granulocytes. As demonstrated in Figure 2(b),
it was predominantly TNF-𝛼 and, to a lesser extent, IL-
1𝛽 that raised the release of MMP8 in whole blood assay.
This TNF-𝛼 effect could not be amplified by IL-17A. Also,
we investigated whether TNF-𝛼 can as well induce MMP8
expression in skin-resident tissue cells. Interestingly, dermal
fibroblasts but not epidermal keratinocytes showed MMP8
expression after TNF-𝛼 stimulation (Figures 3(a) and 3(b)).
Activation of keratinocytes with a mix of TNF-𝛼, IL-17, and
IL-22, a very potent activator for these cells [22], did not result
in significant MMP8 mRNA expression either (Figure 3(b)).
3.3. MMP8 Levels Are Markedly Increased in the Blood of
AI Patients. Then, we asked whether the high MMP8 levels
in lesional AI skin were accompanied by elevated systemic
levels. The analyses of blood samples from 21 AI patients
and 20 control participants disclosed a significant increase
of MMP8 in the blood plasma of AI patients (Figure 4).
Interestingly, there were no differences in the blood levels
of tissue inhibitor of matrix metalloproteinases (TIMP) 4
between AI patients and control participants (Figure 4).
3.4. MMP8 Blood Levels Positively Correlate with AI Severity.
The analysis of potential relationships of MMP8 blood levels
with clinical symptoms revealed thatMMP8 blood levels pos-
itively and significantly correlated with AI severity assessed
by Sartorius score (Table 1). Further analyses revealed an
association between MMP8 blood levels and the number of
regions with inflammatory nodules and fistulas, but not with
scars (Table 1). There was no correlation between MMP8
blood levels and duration of illness, age at AI onset, or patient
age (Table 1 and data not shown), suggesting that MMP8
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areas with scars Duration of AI
Spearman’s correlation coefficient 0.454 0.514 0.486 −0.025 0.103
𝑃 value 0.039 0.017 0.026 0.913 0.666
MMP8 levels were quantified by ELISA in blood from 21 AI patients and were correlated with disease activity measures and duration of AI collected from the

























































Figure 2: TNF-𝛼 stimulates the release ofMMP8 fromneutrophilic granulocytes. (a) Biopsies fromAI lesions were analyzed by IHC. Staining
of myeloperoxidase, an enzyme abundantly expressed in neutrophilic granulocytes, in skin sections counterstained with hematoxylin is
shown. Scale bar = 25 𝜇m. (b) Human blood cultures were stimulated with the indicated AI-relevant cytokines or were left unstimulated
(control) for 4 h. MMP8 concentrations in cell-free supernatants were quantified by ELISA and demonstrated as percent of control. Data
from 5 experiments are shown (mean ± SEM). Significance of differences between control versus stimulation groups was analyzed using the























































































Figure 3: Activated fibroblasts but not keratinocytes expressMMP8. Primary human dermal fibroblasts (a) and keratinocytes (b) were treated
with AI-relevant cytokines as indicated or were left unstimulated (control). Expression was analyzed by RT-qPCR. Data from 3 experiments
are shown (mean ± SEM).










































Figure 4: MMP8 levels are markedly increased in the blood of
AI patients. MMP8 and TIMP-4 blood plasma levels of 20 healthy
control donors and 21 AI patients were analyzed by ELISA. Mean
data ± SEM are shown. Significance of differences was analyzed
using the Mann-Whitney U test (two-tailed; ∗∗𝑃 < 0.01).
levels are associated with the inflammatory activity in this
disease.
3.5. MMP8 Blood Levels Are Associated with Metabolic Alter-
ations. To get hints for further roles of MMP8 in AI, we ana-
lyzed levels of several mediators in blood of AI patients and
correlated them with MMP8 blood levels. As demonstrated
in Figure 5(a), a clear positive association between MMP8
and TNF-𝛼 blood levels was observed, matching very well
our results showing TNF-𝛼 as key MMP8 inducer (Figures
2(b) and 3(a)). Interestingly, we also found a specific negative
correlation between MMP8 and high-density lipoprotein
(HDL) cholesterol blood levels (Figure 5(b)). Furthermore,
there was a positive association between levels of MMP8 and
resistin (Figure 5(c)), a cysteine-rich adipose tissue-derived
peptide hormone that accelerates the accumulation of LDL
in artery walls. Overall, the last data suggest a pathogenetic
role of MMP8 in the metabolic alterations of AI patients.
4. Discussion
AI is a disease with still unknown pathogenesis and inad-
equate therapeutic options. It destructs axillary, inguinal,
gluteal, and perianal regions of very young people, causing
profound pain, large amounts of purulent and malodorous
exudate, and metabolic alterations, and results in reduced
quality of life, social isolation, anddiminished life expectancy.
Evidence for pathogenetically relevant molecules that at
the same time are useful as blood biomarkers for more
exact quantification of AI disease severity may facilitate the
development of novel therapies for these patients.The results
demonstrated in this manuscript suggest that MMP8 is such
a molecule.
We show a strong upregulation of MMP8 in AI lesion
compared to skin from healthy controls and psoriasis
patients. MMP8 is mainly produced by neutrophilic granu-
locytes [21] and this very well matches the observed strong
dermal infiltration of Al lesions by neutrophils and the large
purulent exudates in these patients. In contrast, neutrophilic
infiltration is limited to epidermalMunro’s microabscesses in
psoriasis, and purulence exudates are absent in this disease.
Regarding MMP8 production, we additionally demonstrated
that TNF-𝛼 is a potent inductor of MMP8 in neutrophilic
granulocytes and, moreover, exerts this effect also on fibrob-
lasts. Accordingly, there was a strong positive correlation
between MMP8 and TNF-𝛼 blood levels. It is possible that
bacterial products induce TNF-𝛼 production in lesional
monocytes, macrophages, and neutrophilic granulocytes and
contribute to elevated MMP8 expression.
The major substrate of MMP8 is the collagen type 1 that
forms large collagen fibers inmost connective tissues, includ-
ing the dermis, giving these tissues rigidity and elasticity
[21, 23]. We assume that degradation of this extracellular
matrix component by MMP8 in AI lesions might lead to the
development of skin cavities (abscesses and draining sinus
tracts), as very recently demonstrated for cavities developing
in lung tissue during human pulmonary tuberculosis [24].
Due to the lack of cutaneous MMP8 expression in psoriatic
lesions, abscesses and draining sinus tracts are absent in
psoriasis.
In the last part of our study we demonstrated that the
high lesional MMP8 levels in AI were accompanied by
elevated MMP8 blood levels. Importantly, these levels posi-
tively correlated with disease activity, in particular with their
inflammatory components. We suggest that MMP8 blood
quantification should be incorporated in future clinical trials.
The currently usedmethods for evaluating the disease activity
are often time-consuming (especially with Sartorius’ grading
system) and undoubtedly subjective; deviations commonly
occur when assessment is conducted by different physi-
cians and centers. What is currently needed are laboratory
parameters useful for accurate AI staging, for decision of the
therapeutic regimen, and for assessment of treatment efficacy.
Interestingly, our study also revealed an association
between MMP8 and metabolic alterations in AI patients. In
fact, MMP8 blood levels negatively correlated with HDL-
cholesterol, an antiatherogenic lipid. Accordingly, Salmi-
nen at al. described that MMP8 affects the structure and
antiatherogenic function of apolipoprotein (apo)A-I, the
main protein component of HDL particles [25]. Proteolytic
modification of apoA-I by MMP8 has been found to impair
the first steps of reverse cholesterol transport, leading to
increased accumulation of cholesterol in blood vessel walls
[25]. Furthermore, we observed a strong positive correlation
between MMP8 and resistin blood levels. There is quite clear
evidence that resistin plays an important role in atheroscle-
rosis. It stimulates proinflammatory cytokine expression in
humanmonocytic cells [26] and increases adhesionmolecule
expression and chemokine production by endothelial cells
[27, 28], leading to immune cell extravasation and develop-
ment of atherosclerotic plaques.
In summary, our results demonstrate the strong presence
ofMMP8 in skin lesions and blood of AI patients and suggest
the pathogenetic involvement of this molecule in skin and
systemic alterations observed in AI patients. Moreover, we
propose the use ofMMP8 as biomarker forAI disease activity.









































































Figure 5: MMP8 blood levels correlate with metabolic alterations in AI patients. Concentrations of MMP8, TNF-𝛼, HDL-cholesterol,
triglycerides (TG), and resistin were quantified in blood from 21 AI patients. Data were subjected to Spearman’s rank correlation analysis. 𝑟
𝑆
(Spearman’s rank correlation coefficient) is indicated (∗𝑃 < 0.05, ∗∗𝑃 < 0.01, and ∗∗∗𝑃 < 0.001).
Mediators of Inflammation 7
Competing Interests
The authors declare that they have no competing interests.
Authors’ Contributions
Sylke Schneider-Burrus andRobert Sabat contributed equally
to this work and are co-last authors.
Acknowledgments
The authors would like to acknowledge Brigitte Ketel,
Annette Buss, and Anne Schulze for excellent technical
assistance. Support of the blood biomarker study was
received from theGerman FederalMinistry of Education and
Research (Bundesministerium fu¨r Bildung und Forschung,
https://www.bmbf.de/) (Grant 01ZX1312A to Kerstin Wolk
and Robert Sabat). Furthermore, the work was partly sup-
ported by Deutsche Forschungsgemeinschaft (Grant SFB 650
TP Z2 to Hans-Dieter Volk).
References
[1] G. B. E. Jemec, “Clinical practice.Hidradenitis suppurativa,”The
New England Journal of Medicine, vol. 366, no. 2, pp. 158–164,
2012.
[2] H. H. van der Zee, J. D. Laman, J. Boer, and E. P. Prens,
“Hidradenitis suppurativa: viewpoint on clinical phenotyping,
pathogenesis and novel treatments,”Experimental Dermatology,
vol. 21, no. 10, pp. 735–739, 2012.
[3] Ł. Matusiak, A. Bieniek, and J. C. Szepietowski, “Hidradenitis
suppurativa markedly decreases quality of life and professional
activity,” Journal of the American Academy of Dermatology, vol.
62, no. 4, pp. 706–708.e1, 2010.
[4] B. G. Vazquez, A. Alikhan, A. L. Weaver, D. A. Wetter, and
M. D. Davis, “Incidence of hidradenitis suppurativa and asso-
ciated factors: a population-based study of Olmsted County,
Minnesota,” Journal of Investigative Dermatology, vol. 133, no.
1, pp. 97–103, 2013.
[5] A. Kurek, E. M. Johanne Peters, R. Sabat, W. Sterry, and S.
Schneider-Burrus, “Depression is a frequent co-morbidity in
patients with acne inversa,” Journal of the German Society of
Dermatology, vol. 11, no. 8, pp. 743–750, 2013.
[6] A. Kurek, E.M. J. Peters, A. Chanwangpong, R. Sabat,W. Sterry,
and S. Schneider-Burrus, “Profound disturbances of sexual
health in patients with acne inversa,” Journal of the American
Academy of Dermatology, vol. 67, no. 3, pp. 422–e1, 2012.
[7] R. Sabat, A. Chanwangpong, S. Schneider-Burrus et al.,
“Increased prevalence of metabolic syndrome in patients with
acne inversa,” PLoS ONE, vol. 7, no. 2, Article ID e31810, 2012.
[8] T. Tzellos, C. C. Zouboulis, W. Gulliver, A. D. Cohen, P.
Wolkenstein, and G. B. E. Jemec, “Cardiovascular disease risk
factors in patients with hidradenitis suppurativa: a systematic
review and meta-analysis of observational studies,” British
Journal of Dermatology, vol. 173, no. 5, pp. 1142–1155, 2016.
[9] G. B. E. Jemec and A. B. Kimball, “Hidradenitis suppurativa:
epidemiology and scope of the problem,” Journal of the Amer-
ican Academy of Dermatology, vol. 73, no. 5, supplement 1, pp.
S4–S7, 2015.
[10] M. V. Laffert, P. Helmbold, J. Wohlrab, E. Fiedler, V. Stadie, and
W. C. Marsch, “Hidradenitis suppurativa (acne inversa): early
inflammatory events at terminal follicles and at interfollicular
epidermis,” Experimental Dermatology, vol. 19, no. 6, pp. 533–
537, 2010.
[11] K. Wolk, K. Warszawska, C. Hoeflich et al., “Deficiency of IL-
22 contributes to a chronic inflammatory disease: pathogenetic
mechanisms in acne inversa,” The Journal of Immunology, vol.
186, no. 2, pp. 1228–1239, 2011.
[12] J. Kryczka and J. Boncela, “Leukocytes: the double-edged sword
in fibrosis,” Mediators of Inflammation, vol. 2015, Article ID
652035, 10 pages, 2015.
[13] H. J. Hurley, “Axillary hyperhidrosis, apocrine bromhidrosis,
hidradenitis suppurativa, and familial benign pemphigus,” in
Dermatologic Surgery, R.H. Roegnick andH.H. Roegnick, Eds.,
pp. 717–743, Marcel Dekker, New York, NY, USA, 1989.
[14] K. Sartorius, J. Lapins, L. Emtestam, and G. B. E. Jemec,
“Suggestions for uniform outcome variables when reporting
treatment effects in hidradenitis suppurativa,” British Journal of
Dermatology, vol. 149, no. 1, pp. 211–213, 2003.
[15] J. Revuz, “Modifications to the Sartorius score and instructions
for evaluating the severity of suppurative hidradenitis,” Annales
de Dermatologie et de Venereologie, vol. 134, no. 2, pp. 173–174,
2007.
[16] K. Sartorius, L. Emtestam, G. B. E. Jemec, and J. Lapins, “Objec-
tive scoring of hidradenitis suppurativa reflecting the role of
tobacco smoking and obesity,” British Journal of Dermatology,
vol. 161, no. 4, pp. 831–839, 2009.
[17] K. Wolk, S. Kunz, E. Witte, M. Friedrich, K. Asadullah, and
R. Sabat, “IL-22 increases the innate immunity of tissues,”
Immunity, vol. 21, no. 2, pp. 241–254, 2004.
[18] K. Wolk, K. Witte, E. Witte et al., “IL-29 is produced by
T(H)17 cells and mediates the cutaneous antiviral competence
in psoriasis,” Science Translational Medicine, vol. 5, no. 204,
Article ID 204ra129, 2013.
[19] E. Witte, G. Kokolakis, K. Witte et al., “Interleukin-29 induces
epithelial production of CXCR3A ligands and T-cell infiltra-
tion,” Journal of Molecular Medicine, vol. 94, no. 4, pp. 391–400,
2016.
[20] K.Wolk,H.Mitsui, K.Witte et al., “Deficient cutaneous antibac-
terial competence in cutaneous T-cell lymphomas: role of Th2-
mediated biased Th17 function,” Clinical Cancer Research, vol.
20, no. 21, pp. 5507–5516, 2014.
[21] E. Dejonckheere, R. E. Vandenbroucke, and C. Libert, “Matrix
metalloproteinase8 has a central role in inflammatory disorders
and cancer progression,” Cytokine and Growth Factor Reviews,
vol. 22, no. 2, pp. 73–81, 2011.
[22] E. Witte, G. Kokolakis, K. Witte et al., “IL-19 is a component
of the pathogenetic IL-23/IL-17 cascade in psoriasis,” Journal of
Investigative Dermatology, vol. 134, no. 11, pp. 2757–2767, 2014.
[23] R. Khokha, A. Murthy, and A. Weiss, “Metalloproteinases and
their natural inhibitors in inflammation and immunity,”Nature
Reviews Immunology, vol. 13, no. 9, pp. 649–665, 2013.
[24] C. W. M. Ong, P. T. Elkington, S. Brilha et al., “Neutrophil-
derivedMMP-8 drives AMPK-dependentmatrix destruction in
human pulmonary tuberculosis,” PLoS Pathogens, vol. 11, no. 5,
Article ID e1004917, 2015.
[25] A. Salminen, P. A˚stro¨m, J. Metso et al., “Matrix metallopro-
teinase 8 degrades apolipoprotein A-I and reduces its choles-
terol efflux capacity,”TheFASEB Journal, vol. 29, no. 4, pp. 1435–
1445, 2015.
8 Mediators of Inflammation
[26] N. Silswal, A. K. Singh, B. Aruna, S. Mukhopadhyay, S. Ghosh,
and N. Z. Ehtesham, “Human resistin stimulates the pro-
inflammatory cytokines TNF-𝛼 and IL-12 in macrophages
by NF-𝜅B-dependent pathway,” Biochemical and Biophysical
Research Communications, vol. 334, no. 4, pp. 1092–1101, 2005.
[27] Y. Cho, S.-E. Lee, H.-C. Lee et al., “Adipokine resistin is a key
player to modulate monocytes, endothelial cells, and smooth
muscle cells, leading to progression of atherosclerosis in rabbit
carotid artery,” Journal of the American College of Cardiology,
vol. 57, no. 1, pp. 99–109, 2010.
[28] S. Parolini, A. Santoro, E. Marcenaro et al., “The role of
chemerin in the colocalization of NK and dendritic cell subsets
into inflamed tissues,”Blood, vol. 109, no. 9, pp. 3625–3632, 2007.



















































 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
